Tags

Type your tag names separated by a space and hit enter

Treatment and treatment trials in multiple sclerosis.
Curr Opin Neurol 2007; 20(3):286-93CO

Abstract

PURPOSE OF REVIEW

This review focuses on advances in current and novel treatment approaches in multiple sclerosis.

RECENT FINDINGS

New therapeutic approaches in multiple sclerosis are emerging. Orally available treatment strategies are more acceptable for patients and may improve adherence to therapy. An oral formulation of glatiramer acetate failed to demonstrate efficacy in a clinical trial, but other promising compounds are on the horizon, such as FTY720. Advances are currently being made in use of therapeutic monoclonal antibodies that specifically target key molecules involved in the immunopathogenesis of multiple sclerosis. Natalizumab directed against the adhesion molecule very late antigen-4 represents the first specific antibody to be added to our therapeutic armamentarium for multiple sclerosis. Further evidence that immunomodulation should be initiated as early as possible has been reported.

SUMMARY

Treatment of multiple sclerosis has changed dramatically over the past decade. Enhanced understanding of the immunopathological processes that underlie the disease, advances in biotechnology and development of powerful magnetic resonance imaging technologies, together with improvements in clinical trial design have led to a variety of valuable therapeutic approaches, which are currently being studied in detail.

Authors+Show Affiliations

Department of Neurology, Heinrich-Heine-University, Duesseldorf, Germany.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17495622

Citation

Kieseier, Bernd C., et al. "Treatment and Treatment Trials in Multiple Sclerosis." Current Opinion in Neurology, vol. 20, no. 3, 2007, pp. 286-93.
Kieseier BC, Wiendl H, Hemmer B, et al. Treatment and treatment trials in multiple sclerosis. Curr Opin Neurol. 2007;20(3):286-93.
Kieseier, B. C., Wiendl, H., Hemmer, B., & Hartung, H. P. (2007). Treatment and treatment trials in multiple sclerosis. Current Opinion in Neurology, 20(3), pp. 286-93.
Kieseier BC, et al. Treatment and Treatment Trials in Multiple Sclerosis. Curr Opin Neurol. 2007;20(3):286-93. PubMed PMID: 17495622.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment and treatment trials in multiple sclerosis. AU - Kieseier,Bernd C, AU - Wiendl,Heinz, AU - Hemmer,Bernhard, AU - Hartung,Hans-Peter, PY - 2007/5/15/pubmed PY - 2007/7/26/medline PY - 2007/5/15/entrez SP - 286 EP - 93 JF - Current opinion in neurology JO - Curr. Opin. Neurol. VL - 20 IS - 3 N2 - PURPOSE OF REVIEW: This review focuses on advances in current and novel treatment approaches in multiple sclerosis. RECENT FINDINGS: New therapeutic approaches in multiple sclerosis are emerging. Orally available treatment strategies are more acceptable for patients and may improve adherence to therapy. An oral formulation of glatiramer acetate failed to demonstrate efficacy in a clinical trial, but other promising compounds are on the horizon, such as FTY720. Advances are currently being made in use of therapeutic monoclonal antibodies that specifically target key molecules involved in the immunopathogenesis of multiple sclerosis. Natalizumab directed against the adhesion molecule very late antigen-4 represents the first specific antibody to be added to our therapeutic armamentarium for multiple sclerosis. Further evidence that immunomodulation should be initiated as early as possible has been reported. SUMMARY: Treatment of multiple sclerosis has changed dramatically over the past decade. Enhanced understanding of the immunopathological processes that underlie the disease, advances in biotechnology and development of powerful magnetic resonance imaging technologies, together with improvements in clinical trial design have led to a variety of valuable therapeutic approaches, which are currently being studied in detail. SN - 1350-7540 UR - https://www.unboundmedicine.com/medline/citation/17495622/full_citation L2 - http://Insights.ovid.com/pubmed?pmid=17495622 DB - PRIME DP - Unbound Medicine ER -